AMPLATZER™ Amulet™ Left Atrial Appendage Occluder Randomized Controlled Trial

A study designed to evaluate the safety and effectiveness of the AMPLATZER Amulet Left Atrial Appendage Occluder.

Trial is open for enrollment

• Cooperman Barnabas Medical Center

Assessing the Normal Microbiome and Virome of the Lung: A Pilot Study

Trial is open for enrollment.

• Cooperman Barnabas Medical Center

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO)

Trial is open for enrollment.

• Cooperman Barnabas Medical Center

BiSpectral Index (BIS) Monitoring and Sedation Practices in Critically Ill Mechanically Ventilated Patients: A Single Center, Prospective, Randomized Control Trial

Trial is open for enrollment

• Cooperman Barnabas Medical Center

Enterprise Vascular Remodeling Devices (VRD)

Trial is open for enrollment.

• Cooperman Barnabas Medical Center

ESTEEM - NCT02047097

This Phase IV study follows patients who are newly initiating dimethyl fumarate (Tecfidera) and monitors clinical effectiveness and the incidence of adverse events in routine clinical care.

Type: Observational

Principal Investigator: Andrew Sylvester, MD

Website: ClinicalTrials.gov Identifier: NCT02047097

This study is active, but closed to enrollment.

For inquiries, call (973) 322-7073

• Cooperman Barnabas Medical Center
• Barnabas Health Ambulatory Care Center

ESTEEM KETONE SUB-STUDY

An additional sub-study (Ketone Sub- study) to ESTEEM is being offered to approximately 130 patients who are currently enrolled in ESTEEM at ~25 sites in the US in order to assess urine and serum ketones in DMF-treated patients. After enrollment in the sub-study, serum and urine will be collected at each routine visit to measure the serum and urine ketone levels.

Type: Observational

Principal Investigator: Andrew Sylvester, MD

Website: ClinicalTrials.gov Identifier: NCT02047097

This study is active, and open to enrollment for current study subjects.

• Cooperman Barnabas Medical Center
• Barnabas Health Ambulatory Care Center

FLUENT - NCT03257358

This Phase IV study aims to characterize how certain immune biomarkers change for MS patients while they are receiving fingolimod (Gilenya) 0.5 mg/day.

Type: Observational

Principal Investigator: Andrew Sylvester, MD

Website: ClinicalTrials.gov Identifier: NCT03257358

This study is active, but closed to enrollment.

For inquiries, call (973) 322-7073

• Cooperman Barnabas Medical Center
• Barnabas Health Ambulatory Care Center

Incidence and Risk Factors Associated with Acute Respiratory Failure in Patients after Renal Transplant

Trial is open for enrollment.

• Cooperman Barnabas Medical Center

Incidence of Thrombotic Complications in Patients with COVID-19 Admitted to Saint Barnabas Medical Center

Trial is open for enrollment.

• Cooperman Barnabas Medical Center

IV Methylprednisolone for Progressive MS

This study aims to investigate the effectiveness of IV Methylprednisolone (IV MP) at 1g /day for 5 days v. sub-therapeutic doses of IV MP for 5 days in RMS, RRMS, and SPMS DMT-treated MS patients who are experiencing functional decline in the absence of relapses (progressive MS).

Type: Drug Trial

Principal Investigator: Andrew Sylvester, MD

This study is open to enrollment.

For inquiries, call (973) 322-7073

• Cooperman Barnabas Medical Center
• Barnabas Health Ambulatory Care Center

OCT Study

Evaluation of Immunomodulator Effects on Retinal Nerve Fiber Layer and Macular Volumes in People with Multiple Sclerosis using Ocular Coherence Tomography

Type: Retrospective Chart review

Principal Investigator: Matthew Tremblay, MD, PhD

Website: IRB Study 20-36

• Cooperman Barnabas Medical Center
• Barnabas Health Ambulatory Care Center